Skip to main content
Eisai Co., Ltd. logo

Eisai Co., Ltd. — Investor Relations & Filings

Ticker · 4523 ISIN · JP3160400002 LEI · 353800HDEE0ZYEX4QV91 T Manufacturing
Filings indexed 76 across all filing types
Latest filing 2019-08-01 Interim / Quarterly Rep…
Country JP Japan
Listing T 4523

About Eisai Co., Ltd.

https://www.eisai.com/index.html

Eisai Co., Ltd. is a research-based global pharmaceutical company engaged in the discovery, development, manufacture, and marketing of prescription medicines. The company's primary business activities are concentrated in the therapeutic areas of neurology, with a significant focus on dementia-related diseases, and oncology. Guided by its core "human health care" (hhc) philosophy, Eisai prioritizes the needs of patients and their families. The company is dedicated to developing innovative and targeted treatments for challenging medical conditions and actively promotes initiatives to improve access to medicines in developing and emerging countries.

Recent filings

Filing Released Lang Actions
四半期報告書-第108期第1四半期(2019/04/01-2019/06/30)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (四半期報告書) for Eisai Co., Ltd. covering the first quarter of the 108th fiscal year (April 1, 2019, to June 30, 2019). It contains detailed financial statements, management analysis (MDA), and segment information, which aligns with the definition of an Interim/Quarterly Report (IR). Q1 2020
2019-08-01 Japanese
有価証券報告書-第107期(平成30年4月1日-平成31年3月31日)
Annual Report
2019-06-20 Japanese
四半期報告書-第107期第3四半期(2018/10/01-2018/12/31)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (四半期報告書) filed with the Kanto Local Finance Bureau under the Financial Instruments and Exchange Act. It contains detailed financial statements, management analysis (MDA), and business performance data for the third quarter of the 107th fiscal period (2018-04-01 to 2018-12-31). As it is a comprehensive financial report for a period shorter than a full fiscal year, it falls under the 'Interim / Quarterly Report' category. 9M 2019
2019-02-12 Japanese
四半期報告書-第107期第2四半期(2018/07/01-2018/09/30)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (四半期報告書) filed by Eisai Co., Ltd. in accordance with the Financial Instruments and Exchange Act of Japan. It covers the second quarter of the 107th fiscal period (July 1, 2018, to September 30, 2018). It contains comprehensive financial statements, management analysis (MDA), and business performance data. While it is a formal regulatory filing, it functions as the primary interim financial report for the company. According to the provided definitions, 'Interim / Quarterly Report' (IR) is the correct classification for comprehensive financial reports for periods shorter than a full fiscal year that contain actual financial statements. Q2 2019
2018-11-08 Japanese
四半期報告書-第107期第1四半期(2018/04/01-2018/06/30)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (四半期報告書) for Eisai Co., Ltd. covering the first quarter of the 107th fiscal period (April 1, 2018, to June 30, 2018). It contains detailed financial statements, management analysis of financial conditions, and business results, which aligns with the definition of an Interim/Quarterly Report (IR). Q1 2019
2018-08-09 Japanese
有価証券報告書-第106期(平成29年4月1日-平成30年3月31日)
Annual Report Classification · 100% confidence The document is a Japanese '有価証券報告書' (Yuuka Shouken Houkokusho), which is the standard Japanese equivalent of an Annual Report (10-K). It contains detailed financial statements, management indicators, and corporate history for the fiscal year ending March 31, 2018. It is a comprehensive regulatory filing, not an announcement or a summary. FY 2018
2018-06-20 Japanese

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.